February 2011 Briefing - UrologyLast Updated: March 01, 2011.
Here are what the editors at HealthDay consider to be the most important developments in Urology for February 2011. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Mycophenolate Mofetil and Placebo Show Similar Efficacy
MONDAY, Feb. 28 (HealthDay News) -- Mycophenolate mofetil (MMF) and placebo showed similar efficacy in treating symptoms of refractory interstitial cystitis/painful bladder syndrome (IC/PBS) before the premature termination of the trial, according to a study published in the March issue of The Journal of Urology.
Trial Results May Have Influenced PSA Testing Trend
MONDAY, Feb. 28 (HealthDay News) -- Prostate-specific antigen (PSA) testing of men for prostate cancer appears to have declined slightly since the 2009 publication of trials with conflicting findings on the effect of PSA testing on mortality, according to research published online Feb. 28 in the Journal of the National Cancer Institute.
Androgenic Alopecia Tied to Prostate Cancer Risk
FRIDAY, Feb. 25 (HealthDay News) - Early-onset androgenic alopecia is associated with the development of prostate cancer later in life, according to a study published online Feb. 15 in the Annals of Oncology.
Denosumab May Delay Skeletal-Related Events
FRIDAY, Feb. 25 (HealthDay News) -- Denosumab prevents skeletal-related events for longer than zoledronic acid in patients with castration-resistant prostate cancer with bone metastases, according to research published online Feb. 25 in The Lancet.
Prostate-Specific Antigen Velocity No Indication for Biopsy
FRIDAY, Feb. 25 (HealthDay News) -- A current guideline on early detection of prostate cancer, which recommends biopsy based on high prostate-specific antigen (PSA) velocity even without other indications, may lead to many unnecessary biopsies, according to a study published online Feb. 24 in the Journal of the National Cancer Institute.
Bupropion Improves Sexual Function in Type 2 Diabetes
WEDNESDAY, Feb. 23 (HealthDay News) -- Patients with type 2 diabetes who are treated with bupropion (BU) for major depressive disorder (MDD) show significant improvement in sexual function, according to a study published in the February issue of Diabetes Care.
Partial Nephrectomy Cuts Renal Cancer Death in Elderly
MONDAY, Feb. 21 (HealthDay News) -- Older patients are less likely to die of renal cell carcinoma when treated with partial nephrectomy; however, they are less likely to undergo partial nephrectomy than are younger patients, according to a study published in the February issue of The Journal of Urology.
Low Pay for New Female Doctors Tied to Gender, Not Job
MONDAY, Feb. 21 (HealthDay News) -- In 2008, male physicians who were newly trained in New York State made an average of $16,819 more than newly trained female physicians, compared to a $3,600 difference in 1999, according to a study published in the February issue of Health Affairs.
New U.S. Report on the Nation's Health 2010 Released
WEDNESDAY, Feb. 16 (HealthDay News) -- The U.S. Centers for Disease Control and Prevention's National Center for Health Statistics' 34th annual report, presenting the latest information on health status and determinants, utilization of health care, health care resources, expenditures, and a special feature on death and dying, was published Feb. 16.
Most Recalled Medical Devices Given Lenient Approval
TUESDAY, Feb. 15 (HealthDay News) -- The majority of medical devices recalled from 2005 to 2009 for risk of serious health hazard or death were approved by the less strict 510(k) process intended for devices considered low or moderate risk, according to a study published online Feb. 14 in the Archives of Internal Medicine.
Researchers Explore Nature of Difficult Clinical Encounters
MONDAY, Feb. 14 (HealthDay News) -- Both patients and physicians can bring qualities to a clinical encounter that result in its being perceived as difficult, and patients involved in these types of encounters have worse short-term outcomes, according to research published online Jan. 25 in the Journal of General Internal Medicine.
Test Approved to Monitor Levels of Kidney Rejection Drug
FRIDAY, Feb. 11 (HealthDay News) -- A new test to monitor blood levels of a drug used to prevent rejection in kidney transplant patients has been approved by the U.S. Food and Drug Administration.
Public Sector Plays Big Role in Drug Research
WEDNESDAY, Feb. 9 (HealthDay News) -- Public-sector research institutions (PSRIs) appear to play a bigger role in drug discovery than was previously thought, contributing to the discovery of about 10 to 20 percent of drugs approved for new drug applications since 1990, according to research published in the Feb. 10 issue of the New England Journal of Medicine.
Recommendations for Post-Prostatectomy Radiation Static
MONDAY, Feb. 7 (HealthDay News) -- Recommendations for post-prostatectomy radiation therapy (PPRT) have not increased despite the recent presentation of studies reporting its association with improved biochemical disease-free survival (bDFS), according to research published in the January issue of The Journal of Urology.
CT Imaging Determines Stone Burden Better Than X-Ray
THURSDAY, Feb. 3 (HealthDay News) -- Computerized tomography (CT) determines proximal stone burden better than plain film X-rays do in patients with encrusted and retained ureteral stents, according to a study published in the February issue of The Journal of Urology.
Tumor Recurrence May Predict Stage Progression
WEDNESDAY, Feb. 2 (HealthDay News) -- Frequency of tumor recurrence is a predictor of subsequent stage progression in patients diagnosed with nonmuscle invasive bladder cancer, according to a study published in the February issue of The Journal of Urology.
|Previous: February 2011 Briefing - Surgery||Next: February 2011 Briefing - Internal Medicine|
Reader comments on this article are listed below. Review our comments policy.